Study of Modifications Induced by Continued Direct Oral Anticoagulant Therapy during Atrial Fibrillation Ablation Procedures on Standard Hemostasis Parameters.
Marie MullerJulien GodetXavier DelabrancheLaurent SattlerDavid MillardHalim MarzakPaul Michel MertesAnnick SteibLelia GrunebaumLaurence JeselCharles Ambroise TacquardPublished in: Journal of clinical medicine (2023)
Our results raise the question of optimal management of intra-procedural heparin therapy and highlight the limitations of the ACT test, particularly in patients on apixaban.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- catheter ablation
- end stage renal disease
- ejection fraction
- newly diagnosed
- left atrial
- heart failure
- chronic kidney disease
- prognostic factors
- percutaneous coronary intervention
- stem cells
- oral anticoagulants
- left atrial appendage
- coronary artery disease
- mitral valve
- mesenchymal stem cells
- patient reported
- smoking cessation
- bone marrow